Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 85 of 85 results for menopause

  1. Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions?

    Women with premature ovarian insufficiency can experience the effects of menopause for most of their adult life. This can lead to...

    Research recommendation
    Published
    11 December 2015

  2. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

    NICE guideline
    Published
    20 October 2015
    View recommendations

    Sections for NG16

  3. Benefits of MRI surveillance in women over 50 years:- Research is recommended to establish the risk and benefits of MRI surveillance compared with mammography in women over 50 years with a personal history of breast cancer. Studies should include sub-analysis for breast density. [new 2013]

    Although breast density decreases with age, and particularly after the menopause, there is no sudden change at any particular age. For...

    Research recommendation
    Published
    9 June 2015

  4. Menopause

    All NICE products on menopause. Includes any guidance and quality standards.

    Topic page

  5. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

    Medical technologies guidance
    In development

  8. Women's and reproductive health guidelines

    management in pregnancy, and nutrition in children up to 5 years Menopause: diagnosis and management Polycystic ovary syndrome: diagnosis

    NICE guideline
    In development

  9. Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause (IPG738)

    We have moved interventional procedures guidance 738 to become HealthTech guidance 640. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

    Technology appraisal guidance
    In development